These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16570910)

  • 21. Pathway analysis for design of promiscuous drugs and selective drug mixtures.
    Sivachenko A; Kalinin A; Yuryev A
    Curr Drug Discov Technol; 2006 Dec; 3(4):269-77. PubMed ID: 17430103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fast method development and rapid analysis using a screening approach for enantiomeric separations in capillary electrophoresis.
    Jimidar MI; Van Ael W; Shah R; Redlich D; De Smet M
    J Capill Electrophor Microchip Technol; 2003; 8(5-6):101-10. PubMed ID: 15369174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug interactions.
    Drug Ther Bull; 1967 Nov; 5(23):89-92. PubMed ID: 4964873
    [No Abstract]   [Full Text] [Related]  

  • 24. Merocyanine solvatochromic dyes in the study of synergistic effects in mixtures of chloroform with hydrogen-bond accepting solvents.
    Testoni FM; Ribeiro EA; Giusti LA; Machado VG
    Spectrochim Acta A Mol Biomol Spectrosc; 2009 Jan; 71(5):1704-11. PubMed ID: 18678525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics/molecular mechanics metadynamics simulations.
    Sgrignani J; Grazioso G; De Amici M; Colombo G
    Biochemistry; 2014 Aug; 53(31):5174-85. PubMed ID: 25050826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity assessment of organic contaminants: evaluation of mixture effects in model industrial mixtures using 2n full factorial design.
    Parvez S; Venkataraman C; Mukherji S
    Chemosphere; 2008 Oct; 73(7):1049-55. PubMed ID: 18789476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors.
    Coan KE; Shoichet BK
    J Am Chem Soc; 2008 Jul; 130(29):9606-12. PubMed ID: 18588298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. X-ray crystallographic analysis of IMP-1 metallo-β-lactamase complexed with a 3-aminophthalic acid derivative, structure-based drug design, and synthesis of 3,6-disubstituted phthalic acid derivative inhibitors.
    Hiraiwa Y; Saito J; Watanabe T; Yamada M; Morinaka A; Fukushima T; Kudo T
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4891-4. PubMed ID: 25246278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.
    Nukaga M; Abe T; Venkatesan AM; Mansour TS; Bonomo RA; Knox JR
    Biochemistry; 2003 Nov; 42(45):13152-9. PubMed ID: 14609325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineered Amp C β-lactamase as a fluorescent screening tool for class C β-lactamase inhibitors.
    Tsang MW; Chan PH; So PK; Ma DL; Tsang CW; Wong KY; Leung YC
    Anal Chem; 2011 Mar; 83(6):1996-2004. PubMed ID: 21338058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interpreting steep dose-response curves in early inhibitor discovery.
    Shoichet BK
    J Med Chem; 2006 Dec; 49(25):7274-7. PubMed ID: 17149857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A four-step approach to evaluate mixtures for consistency with dose addition.
    Hertzberg RC; Pan Y; Li R; Haber LT; Lyles RH; Herr DW; Moser VC; Simmons JE
    Toxicology; 2013 Nov; 313(2-3):134-44. PubMed ID: 23146763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Aggregation Advisor for Ligand Discovery.
    Irwin JJ; Duan D; Torosyan H; Doak AK; Ziebart KT; Sterling T; Tumanian G; Shoichet BK
    J Med Chem; 2015 Sep; 58(17):7076-87. PubMed ID: 26295373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A chromogenic cephalosporin for β-lactamase inhibitor screening assays.
    Yu S; Vosbeek A; Corbella K; Severson J; Schesser J; Sutton LD
    Anal Biochem; 2012 Sep; 428(2):96-8. PubMed ID: 22709853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug combinations; feasibilities and limitations].
    Ariëns EJ
    Ned Tijdschr Geneeskd; 1973 Mar; 117(11):434-51. PubMed ID: 4569839
    [No Abstract]   [Full Text] [Related]  

  • 36. Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria.
    Danishuddin M; Khan A; Faheem M; Kalaiarasan P; Hassan Baig M; Subbarao N; Khan AU
    J Biomol Struct Dyn; 2014; 32(5):741-50. PubMed ID: 23600675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-throughput assays for promiscuous inhibitors.
    Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK
    Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Reciprocal effect of drugs].
    Graber H
    Orv Hetil; 1972 Oct; 113(40):2403-5. PubMed ID: 5072983
    [No Abstract]   [Full Text] [Related]  

  • 39. Ultra-performance liquid chromatography/tandem mass spectrometric quantification of structurally diverse drug mixtures using an ESI-APCI multimode ionization source.
    Yu K; Di L; Kerns E; Li SQ; Alden P; Plumb RS
    Rapid Commun Mass Spectrom; 2007; 21(6):893-902. PubMed ID: 17295426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomolar inhibitors of AmpC beta-lactamase.
    Morandi F; Caselli E; Morandi S; Focia PJ; Blázquez J; Shoichet BK; Prati F
    J Am Chem Soc; 2003 Jan; 125(3):685-95. PubMed ID: 12526668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.